The revelation of Pfizer’s CEO about the VOCID vaccine

by

vaccines

Getty Images

Pfizer CEO says a third coronavirus vaccine is not ruled out.

Pfizer Pharmaceutical CEO Albert Bourla has said that those who have received both doses of the COVID-19 vaccine are likely to need a third dose to boost the drug’s effectiveness.

As reported by CNN, Bourla made these statements during a CBS Health company forum. In dialogue with colleagues, the CEO of Pfizer has stated that the evidence shows that the coronavirus vaccine loses effectiveness over the months. This may require a third dose.

“A likely scenario is that a third dose will probably be needed sometime between six and 12 months and then, from there, there will be a revaccination. But all of that needs to be confirmed,” Bourla said.

“If you ask me, I think there will be a need, according to this data, for revaccinations,” the Pfizer CEO added.

It should be noted that Bourla’s words are not official. This is a forecast based on the data available to the pharmaceutical leader.

Pfizer has already announced that its vaccine would guarantee 95% efficacy against serious hospitalizations for up to six months after applying the second dose. This study involved 12,000 vaccinated patients. The company’s scientific team stressed the partial and likely nature of the results.

The United States is evaluating strengthening vaccine doses

In line with the concern of Pfizer and the rest of the pharmaceutical companies, the U.S. government is evaluating the possibility of applying a third dose of the coronavirus vaccine.

This was confirmed by David Kessler, scientific director of response against the COVID-19 of the Joe Biden administration.

Kessler expressed that new variants of the coronavirus could “challenge” the effectiveness of vaccines.

“It sounds strong, but there’s something declining and the variants certainly challenge … they make these vaccines work more. So I think for planning purposes, just for planning purposes, I think we should expect to drive, ”he told the Select Chamber Subcommittee on Coronavirus Response.

The US will invest millions to detect new variants of COVID-19

Joe Biden’s government will invest $ 17 billion to detect new variants of the coronavirus in the United States.

The sum will come from the American Rescue Plan through the Centers for Disease Control and Prevention (CDC). It will be aimed at different states to soon detect the circulation of new variants of the disease.

This is an ambitious plan that consists of tracing the genomic sequence of the viruses registered in the different infected. The United States is already devoted to these studies. The Biden government has allocated $ 200 million, which is equivalent to 29,000 genomic sequences per week.

The new funding would involve greater work capacity. It would also give states the opportunity to have their own resources to conduct their studies without relying on the CDC headquarters.

READ MORE: Joe Biden begins to reverse restrictions on abortion: What action did he take?

Follow Right Now on Instagram

.Source